Moderna's cancer vaccine may be a 'major breakthrough', scientists say

Moderna's cancer vaccine may be a 'major breakthrough', scientists say An experimental vaccine nearly halves the risk of skin cancer returning in high-risk patients, final study results show.

A phase two clinical trial found the shot — developed by Moderna — combined with an immunotherapy drug made by Merck slashed the risk of melanoma coming back by 44 percent compared to those receiving the drug alone. The Daily Mail

See also:

• Adding a Personalized mRNA Cancer Vaccine to Immunotherapy May Prolong Recurrence-free Survival in Patients With High-risk Melanoma American Association for Cancer Research